全文获取类型
收费全文 | 2618篇 |
免费 | 67篇 |
国内免费 | 11篇 |
专业分类
耳鼻咽喉 | 24篇 |
儿科学 | 149篇 |
妇产科学 | 36篇 |
基础医学 | 305篇 |
口腔科学 | 8篇 |
临床医学 | 251篇 |
内科学 | 560篇 |
皮肤病学 | 15篇 |
神经病学 | 222篇 |
特种医学 | 120篇 |
外科学 | 354篇 |
综合类 | 4篇 |
预防医学 | 78篇 |
眼科学 | 15篇 |
药学 | 149篇 |
中国医学 | 1篇 |
肿瘤学 | 405篇 |
出版年
2023年 | 10篇 |
2022年 | 13篇 |
2021年 | 47篇 |
2020年 | 18篇 |
2019年 | 53篇 |
2018年 | 65篇 |
2017年 | 30篇 |
2016年 | 40篇 |
2015年 | 44篇 |
2014年 | 74篇 |
2013年 | 82篇 |
2012年 | 176篇 |
2011年 | 187篇 |
2010年 | 99篇 |
2009年 | 76篇 |
2008年 | 172篇 |
2007年 | 176篇 |
2006年 | 168篇 |
2005年 | 207篇 |
2004年 | 169篇 |
2003年 | 147篇 |
2002年 | 147篇 |
2001年 | 36篇 |
2000年 | 35篇 |
1999年 | 47篇 |
1998年 | 44篇 |
1997年 | 31篇 |
1996年 | 26篇 |
1995年 | 26篇 |
1994年 | 17篇 |
1993年 | 20篇 |
1992年 | 26篇 |
1991年 | 12篇 |
1990年 | 12篇 |
1989年 | 14篇 |
1988年 | 14篇 |
1987年 | 15篇 |
1986年 | 9篇 |
1985年 | 7篇 |
1984年 | 11篇 |
1983年 | 9篇 |
1981年 | 5篇 |
1979年 | 8篇 |
1978年 | 5篇 |
1977年 | 8篇 |
1972年 | 8篇 |
1969年 | 8篇 |
1968年 | 4篇 |
1967年 | 5篇 |
1966年 | 4篇 |
排序方式: 共有2696条查询结果,搜索用时 0 毫秒
61.
Lioure B Béné MC Pigneux A Huynh A Chevallier P Fegueux N Blaise D Witz B Delain M Cornillon J Luquet I Blanchet O Cornillet-Lefebvre P Carré M Hunault M Larosa F Lamy T Randriamalala E Ojeda-Uribe M Berthou C Fornecker L Harousseau JL Bouscary D Ifrah N Cahn JY;GOELAMS 《Blood》2012,119(12):2943-2948
The LAM2001 phase 3 trial, involving 832 patients with acute myeloid leukemia (AML; median: 46 years) proposed HLA-identical sibling allograft HSCT for all patients with an identified donor. The trial compared reduced-intensity conditioning (RIC) for patients older than 50 years of age (N = 47) and myeloablative conditioning for younger patients (N = 117). BM HSCT was performed in the younger patients, while the older ones received a consolidation course, followed by peripheral blood allo-HSCT using RIC. The incidence of grade II-IV acute GVHD, was 51.9% (95% confidence interval [CI]: 42.1-61.8) and 11.3% (1.6-21.2) after myeloablative or RIC, respectively (P < .0001) and that of chronic GVHD 45.8% (95% CI: 34.8-56.7) and 41.7% (24.7-58.6; NS). Cumulative incidence of nonrelapse mortality at 108 months was 15.8% (95% CI: 9.8-23.2) for myeloablative, and 6.5% (0.2-16.2) for RIC (NS). CI of relapse at 108 months was 21.7% (95% CI: 13.9-28.6) and 28.6% (16.5-43.4; NS). Overall survival at 108 months was 63.4% (95% CI: 54.6-72.2) and 65.8% (52.2-72.2), respectively, after myeloablative or RIC (NS). RIC peripheral blood stem cell allo-HSCT is prospectively feasible for patients between the ages of 51 and 60 years without excess of relapse or nonrelapse mortality, and compares favorably with myeloablative marrow allo-HSCT proposed to younger patients. 相似文献
62.
Natarajan-Amé S Park S Ades L Vey N Guerci-Bresler A Cahn JY Etienne G Bordessoule D Ravoet C Legros L Cheze S Stamatoullas A Berger E Schmidt A Charbonnier A Chaury MP Braun T Fenaux P Dreyfus F;Groupe Francophone des Myélodysplasies 《British journal of haematology》2012,158(2):232-237
Marrow cells from patients with higher-risk myelodysplastic syndrome (MDS) exhibit constitutive nuclear factor (NF)-κB activation. The proteasome inhibitor, bortezomib, has limited efficacy as a single agent in acute myeloid leukaemia. Its activity on leukaemic cell lines is potentiated by chemotherapy. We treated 43 higher-risk MDS patients with bortezomib (1·5 mg/m(2) , days 1, 4, 8 and 11) and low dose cytarabine arabinoside (LDAC; 10 mg/m(2) , then 20 mg/m(2) from days 1-14), every 28 d for four cycles. Median follow-up was 29·7 months. Responses were seen in 12 of the 43 patients (28%), including complete response (CR, n = 1), marrow-CR (n = 3), partial response (PR, n = 5) and haematological improvement (HI, n = 3). Responses were seen in 12 (36%) of the 33 previously untreated patients (11% CR, 13% PR, 2·5% HI), compared to none in the 12 previously treated patients (P < 0·01). Responders had better overall survival (median 18·2 vs. 10 months). One CR and 3 marrow-CRs were seen in patients with complex karyotypes. Main toxicity was haematological, responsible for infection in six patients and bleeding in 3. Three patients with Grade 1-2 pre-treatment haematotoxicity developed Grade 3-4 toxicity. Neuropathy was seen in 12% of patients. The addition of bortezomib to LDAC in higher-risk MDS may improve results obtained with LDAC alone, especially in patients with unfavourable karyotypes. 相似文献
63.
64.
Hirsch P Tang R Marzac C Perrot JY Fava F Bernard C Jeziorowska D Marie JP Legrand O 《Haematologica》2012,97(2):241-245
ATP-binding cassette transporter (and specially P-glycoprotein) activity is a well known prognostic factor in acute myeloid leukemia, but when compared to other molecular markers its prognostic value has not been well studied. Here we study relationships between this activity, fms-like tyro-sine kinase 3(FLT3/ITD), nucleophosmin(NPM1), CAAT-enhancer binding protein alpha(CEBPα), and brain and acute leukemia cytoplasmic protein (BAALC), in 111 patients with normal cytogenetics who underwent the same treatment, and evaluate its prognostic impact. Independent factors for survival were age (P=0.0126), ATP-binding cassette transporter activity (P=0.018) and duplications in the fms-like tyrosine kinase 3 (P=0.0273). In the 66 patients without fms-like tyrosine kinase 3 duplication and without nucleophosmin mutation, independent prognostic factors for complete remission achievement and survival were age and ATP-binding cassette transporter activity. In conclusion, ATP-binding cassette transporter activity remains an independent prognostic factor, and could assist treatment decisions in patients with no nucleophosmin mutation and no fms-like tyrosine kinase 3 duplication. 相似文献
65.
Yakoub-Agha I Mary JY Hulin C Doyen C Marit G Benboubker L Voillat L Moreau P Berthou C Stoppa AM Maloisel F Rodon P Dib M Pegourie B Casassus P Slama B Damaj G Zerbib R Harousseau JL Mohty M Facon T;Intergroupe Francophone du Myélome 《European journal of haematology》2012,88(3):249-259
This multicentre prospective randomised trial compared the efficacy and safety of two doses of thalidomide in patients with relapsed or refractory myeloma. The study was designed to test the non-inferior efficacy and to confirm the better tolerability of low-dose thalidomide as compared to a higher dose. Four hundred patients were randomly assigned to receive either 100 or 400 mg/day of thalidomide. Dexamethasone treatment was added in both arms for patients with stable disease or treatment failure at 12 weeks. The primary endpoint was 1-year overall survival (OS). Thalidomide 100 mg/day was better tolerated than 400 mg/day with less high-grade somnolence, constipation, nausea/vomiting and peripheral neuropathy (P < 0.001, P = 0.007, P = 0.03 and P = 0.007, respectively). In the per-protocol population (PP), the estimated 1-year OS rates were of 74.5% (n = 149) and 67.3% (n = 156) in the 400 and 100 groups, respectively. The upper limit of the difference between these rates was of 15.6% higher than the non-inferiority acceptable limit of 12.75%, and the hypothesis of non-inferiority of 100 could not be established (P = 0.14). On the other hand, when intent-to-treat (ITT) population was analysed, the non-inferiority was demonstrated because the 1-year OS rates were of 72.8% (n = 195) and 68.8% (n = 205) in the same groups, leading to an upper limit of the difference of 11.49% lower than the non-inferiority acceptable limit. In addition, in patients alive 12 weeks postrandomisation and those who received thalidomide plus dexamethasone, there were no significant differences in response rates, time to progression, progression-free survival and OS between the two groups. Collectively, low-dose thalidomide 100 mg/day has significant activity in advanced myeloma with an improved safety profile and can be a good salvage therapy in combination with dexamethasone. 相似文献
66.
67.
68.
Abduljabbar M Taheini K Picard JY Cate RL Josso N 《Hormone research in p?diatrics》2012,77(5):291-297
Our goal was to compare phenotype and genotype in two extended Middle-Eastern families affected by persistent Müllerian duct syndrome due to mutations of the type II anti-Müllerian hormone receptor (AMHR-II). The first, consanguineous, family consisted of 6 boys and 2 girls, the second consisted of 4 girls and 2 boys. In family I, 4 boys and 1 girl were homozygous for a stop mutation in the 9th exon of AMHR-II, removing part of the intracellular domain of the protein. In family II, 1 girl and 1 boy were homozygous for a transversion changing conserved histidine 254 into a glutamine. Both homozygous girls were normal. In the homozygous males, the degree of development of Müllerian derivatives was variable. The uterus was well developed in 2 boys of family I and in the patient from family II; however, in 1 subject from family I, Müllerian derivatives were undetectable. Taken together, the diversity of clinical symptoms within the same sibship and the lack of correlation between the development of the Müllerian derivatives and the severity of the molecular defects suggest highly variable penetrance of the abnormal alleles and/or the existence of other genetic or epigenetic modifiers of gene expression. 相似文献
69.
70.
Jean-Yves Jenny Xavier Clement 《European journal of orthopaedic surgery & traumatology : orthopedie traumatologie》2016,26(8):929-935